Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
Calmy
Alexandra
A
Division of aInfectious Diseases, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Hirschel
Bernard
B
Hans
Didier
D
Karsegard
Véronique L
VL
Meier
Christoph A
CA
D000328:Adult; D000886:Anthropometry; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011446:Prospective Studies; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077205:Pioglitazone